Ranbaxy’s mission is to become a Research-based
International Pharmaceutical Company, committed to constantly pushing new
frontiers of knowledge in pursuit of new horizons of science.
Ranbaxy, India’s largest pharmaceutical Company and one
of the Top 10 generic pharma players worldwide, is also one of the largest ANDA
(Abbreviated New Drug Application) filers with the US FDA. USA is the
world’s most developed pharmaceutical market and the largest market for
Ranbaxy. The Company continues to forecast global sales of US$ 5 Bn in 2012.
Ranbaxy is committed to increase its R&D spend of over 7%
of US$ 1 Bn in 2004, to around 10% of its targeted turnover of US$ 2 Bn by
2007. With a state-of-the-art fully operational R&D center housing close to
1000 scientists in three blocks, and a fourth underway, Ranbaxy is fortifying
its capabilities in drug discovery, on course towards destination discovery.
(Size: 5.40 MB )
